Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Fabio Chianelli
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Beta
- 2.36
- Country
- CA
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -15.98
Financials
Net Income
$-223.3KEBITDA
$-155.9KFree Cash Flow
$-84.2KEPS (diluted)
$-0.00Shares Outstanding (diluted)
91.02M+22.3%Operating Expenses
$155.9KCash & Debt
$772.6KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-617.8K | $-0.01 |
| 2025 | $0.00 | $-1.53M | $-0.02 |
| 2024 | $0.00 | $-3.12M | $-0.04 |
| 2023 | $0.00 | $-6.42M | $-0.07 |
| 2022 | $0.00 | $-4.01M | $-0.05 |
| 2021 | $0.00 | $2.66M | $0.04 |
| 2020 | $0.00 | $-23.8K | $-0.00 |
Valuation
PHRRFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
125+0.00%Social Signal Score
Mentions (5)
- Newsnewsfilecorp.com·24d ago·Positive
… New U.S. Peptide Pathway, Led by Colon-Targeted KPV and BPC-157 Toronto, Ontario--(Newsfile Corp. - October 29, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical and technology company advancing pharmaceutical 3D printing for personalized medicine, today announced that it is building a portfolio of personalized peptide products for niche indications on its M3DICINES™ 3D-printed medicines platform, for near-term commercializat…
View source ↗ - Newsnewsfilecorp.com·25d ago·Negative
PharmaTher Submits Orphan Drug and Rare Pediatric Disease Designation Applications to FDA for 3D-Printed Creatine Monohydrate in GAMT Deficiency Lead FDA-track program targets a serious pediatric disease with no FDA-approved treatment and could qualify for a transferable priority review voucher. Highlights Two FDA designation applications submitted for creatine monohydrate in guanidinoacetate methyltransferase (GAMT) deficiency: Orphan Drug Designation (ODD) and Rare Pediatric Disease Designatio
View source ↗ - Newsnewsfilecorp.com·48d ago·Positive
PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES Highlights M3DICINES™ 3D-printed medicines platform. One platform for PharmaTher's proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply.
View source ↗ - Newsnewsfilecorp.com·52d ago·Positive
PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform Agreement opens the U.S. and Canadian markets across all customer segments and lays the foundation for PharmaTher's personalized 503A products, FDA rare disease program, national emergency and medical countermeasures initiatives, and CDMO and white-label services Highlights PharmaTher is now the exclusive distributor in North America of Craft Health's Cra
View source ↗ - Newsnewsfilecorp.com·103d ago·Positive
PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing Potential near-term commercialization through two synergistic business units: (i) a telehealth platform connecting patients with independent licensed healthcare providers and (ii) a North American network of pharmacy-based pharmaceutical 3D-printing systems for compounding medications, together forming a personalized medicine ecosystem Toronto, Ontario--(N
View source ↗
Earnings
Fri, Jan 22(in 2 months)
Consensus estimate $-0.01 per share
Typical surprise +85.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 29$-0.00 vs $-0.01beat
- Thu, Jan 29$-0.00 vs $-0.03beat
- Thu, Sep 26$-0.00 vs $-0.02beat
Estimates and results for PHRRF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in PHRRF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
